Catalent Pharma Solutions

📖 Wiki Page

company1496 wordssynced 2026-04-02

Catalent Pharma Solutions

<div class="infobox">
<div class="infobox-header">Catalent Pharma Solutions</div>
<div class="infobox-content">
<table>
<tr><th>Stock Symbol</th><td>NYSE: CTLT</td></tr>
<tr><th>Headquarters</th><td>Somerset, New Jersey, USA</td></tr>
<tr><th>Founded</th><td>2007 (spin-off from Cardinal Health)</td></tr>
<tr><th>Revenue</th><td>$4.38 billion (FY 2024)</td></tr>
<tr><th>CEO</th><td>Alessandro Maselli (President & CEO)</td></tr>
<tr><th>Employees</th><td>~13,500 globally</td></tr>
<tr><th>Focus Areas</th><td>Oral dose, biologics, clinical supply, cell & gene therapy</td></tr>
</table>
</div>
</div>

Overview

...

Catalent Pharma Solutions

Overview

Mermaid diagram (expand to render)

Catalent Pharma Solutions is a leading global Contract Development and Manufacturing Organization (CDMO) that partners with pharmaceutical, biotech, and consumer health companies to accelerate drug development, manufacturing, and clinical supply solutions. Headquartered in Somerset, New Jersey, with operations spanning more than 50 sites across North America, Europe, and Asia, Catalent plays a critical role in the global pharmaceutical supply chain for neurodegeneration therapeutics["@catalent2025"].

Founded in 2007 as a spin-off from Cardinal Health's pharmaceutical technologies segment, Catalent has grown to become one of the largest and most diversified CDMOs in the world. The company went public on the New York Stock Exchange in 2014 (NYSE: CTLT) and has since expanded through strategic acquisitions. In 2024, Catalent was acquired by an investor consortium led by Blackstone for approximately $16 billion, marking one of the largest private equity transactions in the pharmaceutical services sector["@wikipedia2025"].

Catalent's relevance to Alzheimer's disease and neurodegeneration drug development stems from its comprehensive suite of drug development platforms, including advanced oral dose formulation (softgel capsules, controlled release), biologics manufacturing (monoclonal antibodies, cell & gene therapy), and specialized clinical supply services that are particularly critical for complex CNS clinical trials["@bioinsil2023"].

Business Segments

Catalent operates through four primary business segments that collectively support neurodegeneration drug development:

Oral Dose Solutions

The Oral Dose Solutions segment is the company's largest and most mature business unit, providing comprehensive formulation development and manufacturing services for oral pharmaceuticals. This segment includes:

Softgel Capsules: Catalent is a global leader in sealed hard capsule (SHC) and softgel capsule manufacturing, producing billions of capsules annually for pharmaceutical clients. Softgel technology is particularly relevant for Alzheimer's disease drugs that require enhanced bioavailability, taste masking, or controlled release profiles[@softgel2022].
Compressed Tablets: High-throughput tablet manufacturing including direct compression, wet granulation, and roll compaction processes
Controlled Release: Matrix and reservoir-based controlled release technologies for once-daily or twice-daily dosing of neurodegeneration drugs
Orally Disintegrating Tablets (ODT): For patients with swallowing difficulties, a common issue in elderly AD populations
Modified Release: Targeted delivery to specific regions of the gastrointestinal tract

Relevance to AD: Many Alzheimer's disease drugs require sophisticated oral delivery systems. For example, drugs requiring enhanced brain penetration through active transport mechanisms benefit from Catalent's controlled release and permeability enhancement platforms. Several AD programs in development leverage these capabilities[@oraldose2024].

Biologics

The Biologics segment has grown substantially and now represents Catalent's fastest-growing business unit, driven by the shift toward large molecule therapeutics in neurodegeneration:

Monoclonal Antibody Manufacturing: Mammalian cell culture (CHO-based) manufacturing for antibody therapeutics, including programs targeting amyloid-beta, tau, and neuroinflammatory pathways
Protein Drug Substance: Microbial (E. coli, Pichia) and mammalian expression platforms for recombinant proteins
Fill/Finish: Aseptic filling services for vials, syringes, and pre-filled syringes
Analytical Services: Full characterization and release testing for biologics

Relevance to AD: The success of amyloid-targeting antibodies like lecanemab and donanemab has driven significant investment in anti-amyloid and anti-tau antibody programs. These antibodies require mammalian cell manufacturing, sterile fill/finish, and cold-chain distribution — all capabilities that Catalent provides. The biologics segment supports numerous pre-clinical and clinical-stage antibody programs targeting Alzheimer's disease mechanisms[@biologics2024].

Clinical Supply Solutions

The Clinical Supply segment provides integrated services for managing global clinical trials, which is particularly critical for neurodegeneration programs that often involve:

Comparator Sourcing: Procurement and supply of reference drugs for active-controlled trials
IRT (Interactive Response Technology): Randomization and drug assignment systems
Secondary Packaging: Blinding, over-encapsulation, and patient-friendly packaging
Cold Chain Management: Temperature-controlled logistics for biologics and temperature-sensitive compounds
Direct-to-Patient Services: Home healthcare delivery for decentralized trial designs
Biosample Management: Sample kit manufacturing and logistics

Relevance to AD: Alzheimer's disease clinical trials are among the most complex in drug development, typically involving 18-24 month treatment periods, biomarker-focused endpoints, and multi-site international enrollment. These trials require sophisticated clinical supply chain management that Catalent provides, including specialized packaging for cognitive assessment kits and biomarker sample collection materials[@clinical2023].

Cell & Gene Therapy

Catalent has built significant capabilities in advanced therapy manufacturing:

Gene Therapy Manufacturing: AAV (adeno-associated virus) vector manufacturing for CNS-directed gene therapies
Cell Therapy: Autologous and allogeneic cell therapy manufacturing platforms
Plasmid DNA: cGMP plasmid production for gene therapy vectors

Relevance to AD: While cell and gene therapy for Alzheimer's disease remains largely in pre-clinical stages, several companies are exploring AAV-mediated delivery of neurotrophic factors, gene editing approaches targeting risk genes (APOE4, TREM2), and cell replacement therapies using engineered neural progenitors. Catalent's cell and gene therapy facilities provide manufacturing capacity for these emerging programs.

Manufacturing Capabilities

Global Manufacturing Network

Catalent operates a network of manufacturing facilities across three continents:

| Facility Location | Primary Capabilities | Certifications |
|------------------|---------------------|----------------|
| Somerset, NJ, USA | Oral dose, clinical supply | FDA, EMA, PMDA |
| Bloomington, IN, USA | Biologics fill/finish | FDA, EMA |
| Kansas City, MO, USA | Oral dose (softgels) | FDA, EMA |
| Reading, UK | Biologics, fill/finish | EMA, MHRA |
| Eberbach, Germany | Oral dose, packaging | EMA |
| Anagni, Italy | Oral dose, softgels | EMA |
| Bangkok, Thailand | Clinical supply Asia | FDA, EMA |
| Shanghai, China | Oral dose, biologics | NMPA, FDA |

Softgel Manufacturing Excellence

Catalent's softgel capsule manufacturing is widely recognized as best-in-class:

Liquid-filled softgel capsules: For oil-based formulations, including omega fatty acids and lipid-soluble compounds
Sealed hard capsules: For powder and pellet formulations requiring moisture protection
Enteric-coated capsules: For targeted GI delivery or taste masking applications

This technology is directly relevant to several categories of Alzheimer's disease drugs, including BACE inhibitors requiring enteric coating for stability, PPAR agonists often lipid-based formulations, and anti-inflammatory nutraceuticals in development for MCI/early AD.

Biologics Manufacturing Platform

Catalent's biologics capabilities include:

Upstream Manufacturing:

Ambr 250 modular bioreactor systems for process development
2000L and 5000L bioreactor scales for clinical supply
CHO-K1 and CHO-S cell lines with high productivity platforms

Downstream Processing:

Protein A affinity chromatography (ÄKTA systems)
Ion exchange, hydrophobic interaction chromatography
Ultrafiltration/diafiltration (TFF) for final formulation

Fill/Finish:

Aseptic filling in isolator technology
Vial sizes: 2R, 6R, 10R, 20R
Pre-filled syringe filling
Lyophilization for temperature-sensitive products

Alzheimer's Disease Drug Development Partnerships

Key Collaborations

Catalent partners with numerous companies developing neurodegeneration therapeutics[@adpipeline2024]:

Monoclonal Antibody Programs:

Fill/finish services for multiple amyloid-targeting antibody programs in Phase 2 and Phase 3 development
Anti-tau antibodies: Partnerships with companies developing tau-targeted immunotherapies
Neuroinflammatory modulators: TREM2, C3, and IL-1 pathway targeting antibodies requiring mammalian manufacturing

Oral CNS Programs:

Small molecule CNS drugs: Formulation development for BACE inhibitors, gamma-secretase modulators, and other AD-targeting small molecules
Combination therapies: Multi-drug fixed-dose combinations for improved adherence in AD patients

Contract Manufacturing Relationships

Catalent serves as a critical manufacturing partner for major pharmaceutical companies[@partner2024]:

| Client Type | Services Provided | AD Relevance |
|-------------|-------------------|-------------|
| Large pharma (top 20) | Commercial oral dose, biologics fill/finish | Legacy AD programs, new antibodies |
| Biotech (mid-size) | Clinical supply, process development | Novel mechanisms, targeted therapies |
| Virtual companies | End-to-end development services | Asset development, licensing |
| Generic companies | Commercial manufacturing | Generic AD treatments |

Major customer relationships include partnerships with Bayer, Bristol-Myers Squibb, GlaxoSmithKline, Haleon, Novo Nordisk, Moderna, Pfizer, and Sarepta Therapeutics, several of whom have active neurodegeneration programs.

Financial Performance and Strategic Position

Revenue and Growth

| Fiscal Year | Revenue (USD) | Key Growth Drivers |
|-------------|--------------|-------------------|
| 2024 | $4.38 billion | Biologics expansion, clinical supply |
| 2023 | $4.08 billion | Softgel capacity, Asia expansion |
| 2022 | $3.86 billion | COVID-related services wind-down |

Strategic Investments

Catalent has made significant capital investments to expand neurodegeneration-relevant capabilities:

$140 million expansion of Bloomington, Indiana biologics facility (2023)
$90 million new clinical supply hub in Singapore (2023)
$75 million softgel capacity expansion in Kansas City (2022)
$200 million cell and gene therapy facility upgrades (2022-2024)

Competitive Landscape

| CDMO | Key Strengths | AD Capabilities |
|------|--------------|----------------|
| Catalent | Softgel, biologics, clinical supply | Full-service, global |
| Lonza | Mammalian manufacturing, microbial | Strong biologics |
| Thermo Fisher (Patheon) | End-to-end, API manufacturing | Broad, integrated |
| Cambrex | API development, controlled substances | Small molecules |
| Siegfried | Oral dose, injectables | Mid-scale |

Catalent maintains competitive differentiation through its breadth of capabilities, particularly the combination of oral dose expertise, biologics manufacturing, and clinical supply services that many competitors cannot match as a single provider.

Catalent Pharma Solutions

Catalent Pharma Solutions

Overview

Catalent Pharma Solutions

Overview

Business Segments

Oral Dose Solutions

Biologics

Clinical Supply Solutions

Cell & Gene Therapy

Manufacturing Capabilities

Global Manufacturing Network

Softgel Manufacturing Excellence

Biologics Manufacturing Platform

Alzheimer's Disease Drug Development Partnerships

Key Collaborations

Contract Manufacturing Relationships

Financial Performance and Strategic Position

Revenue and Growth

Strategic Investments

Competitive Landscape

See Also